Macerich Company (The) Common Stock vs Merck & Co., Inc. — how do they compare? Macerich Company (The) Common Stock trades at $22.18 (market cap $6.29B), while Merck & Co., Inc. trades at $150.03 (market cap $363.59B). The key difference: Merck & Co., Inc. is far larger — about 57.8× Macerich Company (The) Common Stock's market cap, and Macerich Company (The) Common Stock pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold Macerich Company (The) Common Stock for 0 Days and Merck & Co., Inc. for 98 Days on average.
| MAC | MRK | |
|---|---|---|
Market Cap | $6.29B | $363.59B |
Volume | 3,158,142 | 8,036,558 |
Sector | Real Estate | Health |
52-Week High | $26.51 | $156.43 |
52-Week Low | $16.20 | $82.49 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $10.97B | $410.35B |
Dividend Yield | 3.07% | 2.31% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Merck (MRK) trades at $141.98, down 2.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. Revenue grew to $65.01B in 2025, with net income of $18.25B and a profit margin of 28.07%. Recent news highlights the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors increased holdings. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending.
The outlook remains positive with a consensus price target of $158.50, implying 11.6% upside, supported by 68% analyst buy ratings. Risks include high P/E of 113.58, debt-to-asset ratio rising to 36.06% in 2025, and competitive pressures in pharmaceuticals. The acquisition strategy may drive growth but carries integration risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.
Read more on MAC →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →